Details

Autor(en) / Beteiligte

• Browne, Sarah K.
• Zaman, Rifat
• Sampaio, Elizabeth P.
• Jutivorakool, Kamonwan
• Rosen, Lindsey B.
• Ding, Li
• Pancholi, Minjal J.
• Yang, Lauren M.
• Priel, Debra Long
• Uzel, Gulbu
• Freeman, Alexandra F.
• Hayes, Carlton E.
• Baxter, Roger
• Cohen, Stuart H.
• Holland, Steven M.

Titel

Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection

Ist Teil von

• Blood, 2012-04, Vol.119 (17), p.3933-3939

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with anti–IFN-γ autoantibodies have impaired IFN-γ signaling, leading to severe disseminated infections with intracellular pathogens, especially nontuberculous mycobacteria. Disease may be severe and progressive, despite aggressive treatment. To address the underlying pathogenic IFN-γ autoantibodies we used the therapeutic monoclonal rituximab (anti-CD20) to target patient B cells. All subjects received between 8 and 12 doses of rituximab within the first year to maintain disease remission. Subsequent doses were given for relapsed infection. We report 4 patients with refractory disease treated with rituximab who had clinical and laboratory evidence of therapeutic response as determined by clearance of infection, resolution of inflammation, reduction of anti–IFN-γ autoantibody levels, and improved IFN-γ signaling.